190 related articles for article (PubMed ID: 17762578)
1. Antiangiogenic therapy for ovarian cancer.
Rosa DD; Clamp AR; Collinson F; Jayson GC
Curr Opin Oncol; 2007 Sep; 19(5):497-505. PubMed ID: 17762578
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
4. Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer?
Dizon DS
Am J Clin Oncol; 2013 Oct; 36(5):519-25. PubMed ID: 21552100
[TBL] [Abstract][Full Text] [Related]
5. Current status of anti-angiogenic agents in the treatment of ovarian carcinoma.
Sánchez-Muñoz A; Pérez-Ruiz E; Mendiola Fernández C; Alba Conejo E; González-Martín A
Clin Transl Oncol; 2009 Sep; 11(9):589-95. PubMed ID: 19775998
[TBL] [Abstract][Full Text] [Related]
6. The role of Cediranib in ovarian cancer.
Orbegoso C; Marquina G; George A; Banerjee S
Expert Opin Pharmacother; 2017 Oct; 18(15):1637-1648. PubMed ID: 28933580
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
Burger RA
Ann Oncol; 2011 Dec; 22 Suppl 8():viii65-viii68. PubMed ID: 22180405
[TBL] [Abstract][Full Text] [Related]
9. The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.
Secord AA; Nixon AB; Hurwitz HI
Gynecol Oncol; 2014 Nov; 135(2):349-58. PubMed ID: 25178997
[TBL] [Abstract][Full Text] [Related]
10. The development and use of vascular targeted therapy in ovarian cancer.
Chase DM; Chaplin DJ; Monk BJ
Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
12. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
[TBL] [Abstract][Full Text] [Related]
13. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
14. Targeted agents in ovarian cancer.
Kristedja TS; Morgan RJ; Cristea M
Womens Health (Lond); 2010 Sep; 6(5):679-94. PubMed ID: 20887168
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
[TBL] [Abstract][Full Text] [Related]
16. Reappraising antiangiogenic therapy for breast cancer.
Kerbel RS
Breast; 2011 Oct; 20 Suppl 3(0 3):S56-60. PubMed ID: 22015294
[TBL] [Abstract][Full Text] [Related]
17. Targeting angiogenesis in ovarian cancer.
Schmitt J; Matei D
Cancer Treat Rev; 2012 Jun; 38(4):272-83. PubMed ID: 21764518
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and ovarian cancer.
Lai GG; Penson RT
Drugs Today (Barc); 2011 Sep; 47(9):669-81. PubMed ID: 21971541
[TBL] [Abstract][Full Text] [Related]
20. Development of antiangiogenic agents for ovarian cancer.
Collinson FJ; Hall GD; Perren TJ; Jayson GC
Expert Rev Anticancer Ther; 2008 Jan; 8(1):21-32. PubMed ID: 18095880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]